Celiac.com 04/24/2024 - First Wave BioPharma, a leading biopharmaceutical company specializing in gastrointestinal (GI) diseases, is set to unveil groundbreaking research on celiac disease at the upcoming 2024 Digestive Disease Week (DDW) Conference. This announcement comes with the acceptance of two abstracts for presentation at the esteemed event, scheduled for May 18-21, 2024, in Washington, D.C.
The first abstract, titled "A Composite Mucosal Scale for Celiac Disease Encompassing both Morphology and Inflammation," will introduce VCIEL, a novel quantitative composite scale. VCIEL combines key histologic measurements—villus height to crypt depth ratio (Vh:celiac disease) and density of intraepithelial lymphocytes (IEL)—to enhance the accuracy of assessing small intestinal mucosal health in celiac disease patients. This innovation promises to revolutionize clinical trials by providing more precise endpoint measurements.
Celiac.com Sponsor (A12):
The second abstract, "Dynamics of Serologic Change to Gluten in Celiac Disease Patients," delves into the complexities of diagnosing celiac disease. The study draws from a vast clinical database to investigate critical aspects, including the impact of gluten reintroduction on seropositivity and the correlation between different tTG-IgA assays. These findings have significant implications for improving diagnostic accuracy and patient management strategies.
James Sapirstein, Chairman and CEO of First Wave BioPharma, expressed excitement about the potential impact of their research on advancing the diagnosis and management of celiac disease. Jack Syage, PhD, President and Chief Operating Officer of First Wave, emphasized the validation of their work through the invitation to present at DDW 2024—a testament to the company's commitment to enhancing understanding and treatment options for individuals with celiac disease.
This pioneering research from First Wave BioPharma represents a significant step forward in the quest for precision diagnostics and targeted therapies for celiac disease, offering hope for improved outcomes and quality of life for affected individuals.
Read more at: Stockhouse.com
Recommended Comments
There are no comments to display.
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now